Butalbital, Aspirin, and Caffeine
Brand Names: Butalbital, Aspirin, and Caffeine Generic
Methodology & AI Transparency ⓘ
Butalbital, Aspirin, and Caffeine Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: INDICATIONS Butalbital, Aspirin, and Caffeine Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache.
- 2 Real-world patient consensus: Real-world cohort score of 76% across 18 de-identified Butalbital, Aspirin, and Caffeine entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $46.90 mail/discount cash up to $114.91 uninsured retail (federal NADAC $0.9482).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Butalbital, Aspirin, and Caffeine: nausea (10.1%), headache (8.7%), dizziness (8%).
Ask our AI Specialists anything about Butalbital, Aspirin, and Caffeine
Butalbital, Aspirin, and Caffeine Mechanism, CYP450 Pathways & DailyMed Monograph
INDICATIONS Butalbital, Aspirin, and Caffeine Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. y and safety of Butalbital, Aspirin, and Caffeine Capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.
CLINICAL PHARMACOLOGY Pharmacologically, Butalbital, Aspirin, and Caffeine Capsules combines the analgesic properties of aspirin with the anxiolytic and muscle relaxant properties of butalbital. The clinical effectiveness of Butalbital, Aspirin, and Caffeine Capsules in tension headache has been established in double-blind, placebo-controlled, multi-clinic trials. A factorial design study compared Butalbital, Aspirin, and Caffeine Capsules with each of its major components.
Following administration (50 mg/1 / 325 mg/1 Capsule), Butalbital, Aspirin, and Caffeine achieves Consistent 47%–59% gastrointestinal absorption profile for Butalbital, Aspirin, and Caffeine bioavailability and cmax attained 2–3 hours post-administration of butalbital, aspirin, and caffeine onset, governed by a Elimination kinetics span 5 to 14 hours per Butalbital, Aspirin, and Caffeine clinical pharmacology terminal half-life through systemic clearance of butalbital, aspirin, and caffeine integrates hepatic phase ii conjugation with renal filtration.
Before initiating Butalbital, Aspirin, and Caffeine at 50 mg/1 / 325 mg/1 Capsule, clinical safety checklists rule out contraindications butalbital, aspirin, and caffeine capsules is contraindicated under the following conditions: hypersensitivity or intolerance to aspirin, caffeine, or butalbital.; previous anaphylactoid or exfoliative reaction attributed to butalbital, aspirin, and caffeine. Logged tolerability patterns center on nausea (10.1% of reports), headache (8.7% of reports), dizziness (8% of reports).
Concomitant MAOI therapy potentiates hazardous biogenic amine accumulation during Butalbital, Aspirin, and Caffeine treatment.
Monitor kidney function and gastrointestinal symptoms when Butalbital, Aspirin, and Caffeine overlaps with daily NSAID analgesia.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Butalbital, Aspirin, and Caffeine Capsules is contraindicated under the following conditions: Hypersensitivity or intolerance to aspirin, caffeine, or butalbital.
- Previous anaphylactoid or exfoliative reaction attributed to Butalbital, Aspirin, and Caffeine
Logged Side-Effect Incidence (18 Reports)
Butalbital, Aspirin, and Caffeine Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Butalbital, Aspirin, and Caffeine)
Human clinical trial evidence for Butalbital, Aspirin, and Caffeine is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Butalbital, Aspirin, and Caffeine Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.9482/unit (~$28.45/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $114.91 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $46.90 / mo | View logs ↓ |
Butalbital, Aspirin, and Caffeine Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Butalbital, Aspirin, and Caffeine RxNorm Concept ID | 238134 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.9482 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $114.91 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $46.90 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Butalbital, Aspirin, and Caffeine Patient Community, Cohort Filters & Dosage Logs
Cross-verified Butalbital, Aspirin, and Caffeine (barbiturate) monograph synthesizing RxNorm 238134, openFDA FAERS signals, and $46.90–$114.91 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Butalbital, Aspirin, and Caffeine community threads and patient logs by age, biological sex, dosage, and treatment duration.